The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis

NCT02765399 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide affects fat levels in the liver and blood after meals in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 23 people

Who can join Ages 30–75 · all sexes

Timeline Started 2015-02 · est. completion 2019-02

Where 1 site · Finland

What this study is testing ClinicalTrials.gov NCT02765399 ↗

Description as written by the study sponsor.

This study aims to evaluate the mechanisms underlying the effect of incretin therapy on lipoprotein metabolism in subjects with type 2 diabetes and to study the effect of liraglutide on hepatic de novo lipogenesis.

Treatments tested

Liraglutide also known as Victoza Drug
Placebo Drug

Main thing measured	Change in Liver Fat Content
Sponsor	Helsinki University Central Hospital
Conditions studied	Type 2 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02765399 ↗